Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system

Circulation

Volumn 102, Issue 2, 2000, Pages 253-259

  Tamura, Tetsutaro ^a   Said, Suleman ^a   Harris, Jennifer ^a   Lu, Wenyan ^a   Gerdes, A Martin ^a  

^a SANFORD RESEARCH   (United States)

Author keywords

Drugs; Heart failure; Hypertension; Myocytes; Remodeling

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN; ENALAPRIL; HYDRALAZINE; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SIZE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODYNAMICS; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0034636832     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.2.253     Document Type: Article

References (41)

1. Pfeffer JM, Pfeffer MA, Mirsky I, et al. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A. 1982;79: 3310-3314.
2. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation. 1996;94:2285-2296.
3. Francis GS. Changing the remodeling process in heart failure: basic mechanisms and laboratory results. Curr Opin Cardiol. 1998;13: 156-161.
4. Bohm M, Castellano M, Agabiti-Rosei E, et al. Dose-dependent dissociation of ACE-inhibitor effects on blood pressure, cardiac hypertrophy, and β-adrenergic signal transduction. Circulation. 1995;92:3006-3013.
5. i regulatory mechanisms. Hypertension. 1998;31:961-967.
6. Nunez E, Hosoya K, Susic D, et al. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension. 1997;29:519-524.
7. Kai T, Sugimura K, Shimada S, et al. Inhibitory effects of a subdepressor dose of L-158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin-angiotensin system in double transgenic mice with hypertension. Jpn Circ J. 1998;62:599-603.
8. Kaneko K, Susic D, Nunez E, et al. Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens. 1996;14:645-653.
9. Brodsky S, Gurbanov K, Abassi Z, et al. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Hypertension. 1998;32:746-752.
10. Onodera T, Tamura T, Said S, et al. Maladaptive remodeling of cardiac myocyte shape begins long before failure in hypertension. Hypertension. 1998;32:753-757.
11. Gerdes AM, Onodera T, Wang X, et al. Myocyte remodeling during the progression to failure in rats with hypertension. Hypertension. 1996;28: 609-614.
12. Litwin SE, Katz SE, Weinberg EO, et al. Serial echocardiographic Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy: chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation. 1995;91: 2642-2654.
13. Zierhut W, Zimmer HG, Gerdes AM. Effects of angiotensin-converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats. Circ Res. 1991;69:609-617.
14. Gerdes AM, Moore JA, Hines JM, et al. Regional differences in myocyte size in normal rat heart. Anat Rec. 1986;215:420-426.
15. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
16. Siegl PK, Chang RS, Mantlo NB, et al. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1992;262:139-144.
17. Chang RS, Siegl PK, Clineschmidt BV, et al. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1992;262:133-138.
18. Zafeiridis A, Jeevanandam V, Houser SR, et al. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998; 98:656-662.
19. Tamura T, Onodera T, Said S, et al. Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (SHHF) rat. J Mol Cell Cardiol. 1998;30:2175-2181.
20. Bai S, Campbell SE, Moore JA, et al. Influence of age, growth, and sex on cardiac myocyte size and number in rats. Anat Rec. 1990;226:207-212.
21. Agabiti-Rosei E, Muiesan ML. Left ventricular hypertrophy: how to influence an important risk factor in hypertension. J Hypertens. 1998; 16(suppl 1):S53-S58.
22. Haider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32:1454-1459.
23. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
24. Gerdes AM, Onodera T, Tamura T, et al. New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. J Card Fail. 1998;4:343-348.
25. Kojima M, Shiojima I, Yamazaki T, et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation. 1994;89: 2204-2211.
26. Gerdes AM, Capasso JM. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol. 1995; 27:849-856.
27. Kato H, Suzuki H, Tajima S, et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens. 1991;9: 17-22.
28. Miyata S, Haneda T. Hypertrophic growth of cultured neonatal rat heart cells mediated by type 1 angiotensin II receptor. Am J Physiol. 1994;266: H2443-H2451.
29. Bartunek J, Weinberg EO, Tajima M, et al. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation. 1999;99:22-25.
30. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest. 1997;99:1926-1935.
31. Siragy HM, Inagami T, Ichiki T, et al. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A. 1999;96:6506-6510.
32. McDonald KM, Mock J, D'Aloia A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 1995; 91:2043-2048.
33. Zhu YC, Zhu YZ, Gohlke P, et al. Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am J Cardiol. 1997;80: 110A-117A.
34. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitors in normotensive and hypertensive subjects. N Engl J Med. 1998;339: 1285-1292.
35. Davie AP, Dargie HJ, McMurray JJV. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation. 1999;100:268-273.
36. Mukherjee D, Sen S. Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: role of blood pressure. J Mol Cell Cardiol. 1993; 25:185-196.
37. Hamawaki M, Coffman TM, Lashus A, et al. Pressure-overload hypertrophy is unabated in mice devoid of AT1A receptors. Am J Physiol. 1998;274:H868-H873.
38. Kudoh S, Komuro I, Hiroi Y, et al. Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type 1a receptor knockout mice. J Biol Chem. 1998;273:24037-24043.
39. Tamura T, Said S, Gerdes AM. Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension. 1999;33: 676-680.
40. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol. 1999;33:1948-1955.
41. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998;113:867-869.